April 2022 Update: BioGX in silico analysis of SARS-CoV-2 Variants of Concern
BioGX continuously monitors the evolution of COVID-19 variants to ensure our market leading SARS-CoV-2 RT-PCR tests will continue to detect emerging variants without impacting performance.
BioGX has completed in-silico analysis of over 2.5 million SARS-CoV-2 genome sequences available as of March 31, 2022. Sequence analysis compared the available Omicron genomes against the SARS-CoV-2 nucleocapsid (N-gene) and envelope (E-gene) , targeted by BioGX products. In-silico analysis and empirical testing of the Omicron variant confirmed the gene mutations will not affect the performance of the BioGX portfolio of SARS-CoV-2 products.
BioGX portfolio of SARS-CoV-2 products
- BioGX Xfree™ COVID-19 Direct RT-PCR – FDA EUA
- BD BioGX SARS-CoV-2 Reagents for BD MAX™ System
- BioGX SARS-CoV-2 HMP – N1, N2 & RNase P Multiplex
- BioGX COVID-19, Flu A, Flu B, RSV RT-PCR for BD MAX™
- BioGX SARS-CoV-2 N1, N2, E-gene (RUO)
- BioGX SARS-CoV-2 N1, Flu A, Flu B, RSV A/B (RUO)
| U.S. CDC and WHO Variants of Concern* | % Clades detected by targets | ||||||||
| WHO designation | Pango lineage | GISAID
clade |
Nextstrain clade | Spike Protein
(a.a. changes) |
Region Initially Documented (Date) | No. Sequences Analyzed
(Date) |
N1 | N2 | E |
| Alpha | B.1.1.7
Q.x |
GRY | 20I (V1) | 69del, 70del, 144del, (E484K**),(S494P**),N501Y, A570D, D614G, P681H, T716I, S982A, D1118H, (K1191N**) | United Kingdom (SEP 2020) | 428,332
(31MAR2022) |
>99% | ||
| Beta | B.1.351
B.1.351.2 B.1.351.3 |
GH/501Y.V2 | 20H (V2) | L18F, D80A, D215G, 241del, 242del, 243del, K417N, E484K, N501Y, D614G, A701V | South Africa (MAY 2020) | 26,051
(31MAR2022) |
>99% | ||
| Gamma | P.1
P.1.x |
GR/501Y.V3 | 20J (V3) | 681H,L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I | Brazil
(NOV 2020) |
80,477
(31MAR2022) |
>99% | ||
| Delta | B.1.617.2
AY.x |
G/478K.V1 | 21A, 21I, 21J | 417N, T19R, (V70F**), T95I, G142D, E156-, F157-, R158G, (A222V**), (W258L**), (K417N**), L452R, T478K, D614G, P681R, D950N | India
(OCT 2020) |
1,664,949
(31MAR2022)) |
>99% | ||
| Omicron | B.1.529
BA.x☨ |
GR/484A | 21K, 21L, 21M | +R346K | Multiple Countries
(NOV 2021) |
314,442
(31MAR2022) |
>99% | ||
*Variants of concern being monitored by US CDC and WHO.
**Present in a subset of sequences.
☨BA.2 is a sub- lineage of Omicron variant
